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Abstract
Purpose To compare the clinical outcome
with different treatment regimens in
Acute Adenoviral Keratoconjunctivitis
(AAK).
Methods The records of 110 patients
diagnosed as AAK in two tertiary eye care
centers were evaluated retrospectively. The
treatment regimen, follow-up duration, time
until improvement of the symptoms, visual
acuity, clinical findings, Schirmer’s test and
the Ocular Surface Disease Index (OSDI)
score at the first day, first week and third
week were recorded. The Kruskal–Wallis Test
and Chi-square test were used for comparison
of quantitative and categorical variables,
respectively.
Results Forty six patients were receiving
topical corticosteroids (Group 1), 32 topical
2% Cyclosporin A (CsA) (Group 2) and
32 only artificial tears (Group 3). Mean time
until resolution of the symptoms was lowest
in Group 1 (9.5± 4.9 days) and highest
in Group 3 (13.3± 4.2 days)(p: 0.001).
OSDI scores at the first and third weeks
were highest in Group 3 (52.4± 16.4 and
32.3± 13.0) and lowest in Group 1 (41.0± 21.3
and 23.9± 13.2)(p: 0.01 and p: 0.009). At day
21, percentage of the patients with
subepthelial infiltrates was the highest in
Group 3 (63.4%) and lowest in Group 1
(42.5%).
Conclusions The symptoms were less severe
and had a shorter duration with topical
corticosteroids and CsA when compared with
palliative therapy. Topical 2% CsA may
inhibit development of corneal subepithelial
infiltrates when used in the acute phase of
infection, similar to corticosteroids.
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Introduction
Acute adenoviral keratoconjunctivitis (AAK),
which was first described by Fuchs1 in 1889 is
the most common external ocular viral infection
worldwide. It may present epidemically or
sporadically and is highly contagious. The
natural course of the acute phase of AAK has a
wide spectrum of duration and intensity of
local symptoms. After an incubation period
of 2–14 days, typical symptoms including
conjunctival hyperaemia and chemosis, swelling
of the conjunctival plica, and intense tearing
usually begin in one eye.2 Different from other
forms of viral conjunctivitis, corneal
involvement and impaired vision are important
complications of AAK. During the course of the
infection, ~ 10 days after onset of the symptoms,
corneal subepithelial opacities frequently
develop.
The American Academy of Ophthalmology
Preferred Practice Pattern proposes symptomatic
treatment in the form of artificial tears, topical
antihistamines, or cold compresses to mitigate
symptoms and states that there is inadequate
evidence to support the use of available antiviral
agents for treating adenoviral conjunctivitis.3
The use of topical steroids is recommended only
to reduce scarring in severe cases of adenoviral
keratoconjunctivitis with marked chemosis, lid
swelling, epithelial sloughing, or membranous
conjunctivitis. However, short term topical
steroids are still used with an aim to decrease
patient discomfort.4
Cyclosporine A, which is a well known
immunosuppressive agent, has been used for the
prevention of transplant rejections for a long
time.5 Topical Cyclosporine A (CsA) has been
used effectively in the treatment of many ocular
surface diseases such as keratoconjunctivitis
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sicca,6 atopic and vernal keratoconjunctivitis,7 ulcerative
keratitis,8 and Thygeson’s punctate keratitis.9 It has also
been used in varying concentrations between 0.5 and 2%
for eradicating the symptoms and minimising the
recurrences of corneal subepithelial infiltrates in acute
adenoviral keratoconjunctivitis.10–13 Virustatic agents
such as trifluridine, vidarabine, ganciclovir, and cidofovir
have been found to be only mildly effective or entirely
ineffective against adenoviral diseases, whether in vitro,
in vivo, or in human clinical trials.14–16 Povidone-iodine is
a non-causally-directed treatment option for AAK with a
virucidal effect on adenoviruses. It was reported that
povidone iodine reduced viral load and the severity of
symptoms in vitro and in vivo studies for the treatment of
epidemic keratoconjunctivitis.17,18 However, there are no
controlled trials supporting the use of this non-specific
treatment option.
There is still need for a safe and effective treatment
modality to reduce patient discomfort, morbidity, absence
time from school or work and to prevent developement
of vision altering complications such as corneal
subepithelial infiltrates. Although there are reports that
show the efficacy of topical CsA (1 and 2%) in decreasing
the incidence of corneal opacities and in the therapy
of active subepithelial infiltrates during the chronic
phase,11–13,19,20 there are no studies reported to compare
the safety and efficacy of topical Cyclosporine A with
topical corticosteroids and palliative treatment in acute
adenoviral keratoconjunctivitis. Therefore, we aimed to
compare the clinical outcome with different treatment
regimens including topical corticosteroids, Cyclosporin A
and exclusively palliative therapy, in a large group of
patients who admitted to two tertiary eye care centers.
Patients and methods
The study was approved by the Institutional Review Board
of Baskent University Faculty of Medicine and adhered to the
tenets of the Declaration of Helsinki. The records of the
patients diagnosed as AAK in two tertiary eye care centers
between April 2014 and September 2015 were evaluated
retrospectively. The treatment regimen, follow-up duration,
visual acuity, intraocular pressure, clinical findings including
conjunctival injection, chemosis and subepithelial infiltrates,
Schirmer’s test results and the Ocular Surface Disease Index
(OSDI) score at the first day, first week and third week, as
well as the length of time until subjective improvement of the
typical distressing symptoms were recorded in an unblinded
fashion. We aimed to include only cases of adenoviral
infection with a potential corneal involvement, avoiding cases
of only mild adenoviral conjunctivitis. Therefore, we only
included patients with marked conjunctival injection,
swelling of the eyelids, and epiphora. Patients with any other
ocular anterior segment morbidity, pregnant women, or
patients using any other topical ocular medication were
excluded from analysis. In all patients, diagnosis was
confirmed by an in-office lateral flow immunoassay, RPS
Adeno Detector (Rapid Pathogen Screening Inc., Sarasota,
Florida, USA). The test is capable of detecting all 53
adenoviral serotypes by targeting the conserved hexon
protein. Compared with PCR, the sensitivity was reported to
be 89% and the specificity 94%.21 Patients were included in
the statistical analysis if they were receiving either one of the
3 following treatment regimens, and were examined in the
first and third weeks of therapy:
1. Topical 1% prednisolone acetate+non-preserved artifi-
cial tears (Group 1)
2. Topical 2% Cyclosporine A+non-preserved artificial
tears (Group 2)
3. Only non-preserved artificial tears (Group 3)
The patients were not randomised for a particular
treatment, because of the retrospective nature of the study.
All patients were examined by one of the three experienced
ophthalmologists (DDA, LA or EŞÖ). The choice of the
treatment regime at the time was dependant on the clinical
preference of the attending ophthalmologist and the
preference of the patient. Topical Cyclosporine A treatment
was preferred mostly by patients with a relatively higher
socioeconomic status, due to the higher cost of the
treatment. Topical Cyclosporine A 2% was compounded in
a carboxymethylcellulose vehicle (noncommercialized;
prepared in the pharmacy of Baskent University Hospital,
Ankara, Turkey). The 2% dosage was preferred because it
was the highest dosage reported to be used topically for
epidemic keratoconjunctivitis19 without any systemic or
local side effects, except for a case of childhood phlyctenular
keratoconjunctivitis who developed a generalised skin rash
under CsA 2% therapy.22 The eye with a worse clinical
picture was included in bilateral cases.
A potent corticosteroid formulation was selected for the
treatment, since short-term treatment of AAK with topical
corticosteroids of limited potency may also delay viral
clearance, similar to more potent formulations.23 The
following parameters were recorded by a clinical score
similar to described by Hillencamp at al. previously:24
1. Conjunctival injection: 0=no, 1=mild, 2= severe
2. Conjunctival chemosis: 0=no, 1=mild, 2= severe
3. Corneal subepithelial infiltrates: 0=no, 1= few (⩽10),
2=many (410)
4. Schirmer’s test (with topical anaesthesia): 0=415 mm,
1= 5–15 mm, 2=o5 mm
The sum of these clinical scores was calculated for
each visit.
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All data were analysed for homogeneity of variance.
The Kruskal–Wallis Test was used to evaluate the group
differences for quantitative variables including age, sum
of clinical scores, OSDI score, visual acuity, intraocular
pressure, and the time until subjective improvement of
the symptoms. The Mann–Whitney U test was used to
determine the specific inter-group differences when there
was a significant group difference determined by the
Kruskal–Wallis Test. For categorical variables including
clinical scores for conjunctival injection, conjunctival
chemosis, corneal subepithelial infiltrates, and the
Schirmer’s test, the inter-group differences were analysed
by Chi-square test. We used the SPSS 15.0 software (SPSS
Inc., Chicago, IL, USA).
Results
Hundred and ten eyes of 110 patients (M/F= 54/66) with
a minimum follow-up duration of three weeeks were
included in the study. All patients were under palliative
therapy with non-preserved artificial tears. Forty six
patients (41.8%) were receiving topical corticosteroids
(Group 1), 32 (29%) were receiving topical 2%
Cyclosporin A (Group 2) and 32 (29%) were using only
artificial tears (Group 3). All patients received topical
lubricants for 33.6± 5.6 days after the initial diagnosis.
The mean duration of treatment with topical
corticosteroids was 8.3± 2.7 days in Group 1, and the
mean duration of treatment with topical CsA was
27.5± 4.8 days in Group 2. The mean age of the patients
was (mean± SD) 35.2± 15.8, 33.4± 14.6, 31.9± 16.5 years
in Groups 1, 2, and 3, respectively (P= 0.60).
At presentation, there was no significant difference
among groups in terms of Snellen Best Corrected Visual
Acuity, intraocular pressure (IOP), OSDI scores or the
mean sum of clinical scores (P= 0.18; 0.55; 0.47 and 0.06
respectively). There was no significant difference between
the mean Snellen best corrected visual acuity of the 3
groups, at the first (P= 0.16) and third (P= 0.84) week of
treatment. There was no decrease in visual acuity with
respect to the initial examination in any patient, except for
one patient in Group 1 who had a loss of one line due to
the development of subepithelial infiltrates which were
unresponsive to medical treatment. The mean and SD of
the variables and the respective p values for IOP, OSDI
scores and sum of clinical scores at day 7 and 21, as well
as the length of time until the resolution of the subjective
symptoms in each group are given in Table 1.
There were significant inter-group differences for the
OSDI scores at days 7 (P= 0.04) and 21 (P= 0.03). The
mean sum of clinical scores were also significantly
different between groups at day 21 (P= 0.02). There was
also significant difference between groups in terms of the
mean length of time until the resolution of the subjective
symptoms (Po0.01). The results of the analysis for the
evaluation of inter-group differences for the variables
with a significant group difference are given in Table 2.
The Ocular Surface Disease Index score at day 7 was
the highest in Group 3 (52.4± 16.4)and the lowest in
Group 1 (41.0± 21.3) (P= 0.01). At day 21, the OSDI score
was also the highest in Group 3 (32.3± 13.0) and the
lowest in Group 1 (23.9± 13.2) (Po0.01). At the 7th and
21st days, Group 2 was not significantly different from
Groups 1 and 3 in terms of OSDI scores.
Table 1 The mean and SD of the variables and the respective p values for IOP (mmHg), OSDI scores and sum of clinical scores at day 7
and 21 in each group
Group 1 (mean± SD) Group 2 (mean±SD) Group 3 (mean± SD) P value
IOP (mmHg) (Day 7) 17.3± 3.3 16.2± 3.5 16.9± 2.7 0.247
OSDI score (Day 7) 41.0± 21.3 48.6± 21.2 52.4± 16.4 0.041a
Sum of CS (Day 7) 2.0± 1.3 2.5± 1.3 3.0± 2.1 0.097
IOP (mmHg) (Day 21) 16.8± 2.8 15.6± 3.0 16.4± 1.9 0.175
OSDI score (Day 21) 23.9± 13.2 26.9± 12.4 32.3± 13.0 0.026a
Sum of CS (Day 21) 0.7± 0.8 1.5± 1.1 1.9± 1.2 0.016a
Time until the resolution of the symptoms (Days) 9.5± 4.9 11.2± 4.9 13.3± 4.2 0.005a
Abbreviations: CS, Clinical score; IOP, Intraocular pressure; OSDI, Ocular Surface Disease Index. aSignificant difference.
Table 2 The results of the analysis (p values) of specific inter-group differences for the variables with a significant group difference
OSDI score (Day 7) OSDI score (Day 21) Sum of CS (Day 21) Time until the resolution of the
subjective symptoms (Days)
Group 1–2 P values 0.107 0.246 0.554 0.152
Group 1–3 P values 0.010a 0.009a 0.011a 0.001a
Group 2–3 P values 0.479 0.076 0.028a 0.050a
Abbreviations: CS, Clinical score; OSDI, Ocular Surface Disease Index. aSignificant difference.
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The mean sum of clinical scores was highest in Group 3
at days 7 and 21. At day 7 this difference was not
significant (P= 0.10); however at day 21 there was a
significant difference (P= 0.02). At day 21, the mean sum
of clinical scores in Group 3 (1.9± 1.2) was significantly
higher than Groups 1 (0.7± 0.8) and 2 (1.5± 1.1) (P= 0.01
and 0.03, respectively). There was no significant
difference between the mean sum of clinical sores of
Group 1 and Group 2 at any visit.
The mean time until the resolution of the subjective
symptoms was significantly different between groups
(P= 0.005). It was the lowest in Group 1 with
9.5± 4.9 days and highest in Group 3 with 13.3± 4.2 days
(P= 0.001). There was no significant difference between
Groups 1 and 2 (P= 0.152). The difference between
Groups 2 and 3 was tenuous at P= 0.050.
The clinical scores for conjunctival injection,
conjunctival chemosis, corneal subepithelial infiltrates
(CSE), and the Schirmer’s test in 3 groups were also
seperately analysed for each visit. At the initial visit, there
was no significant difference between groups in terms of
each clinical score. There was no significant difference
among groups in terms of clinical scores for conjunctival
injection, conjunctival chemosis, and Schirmer’s test at
any visit.
There was no significant difference between the clinical
scores for CSE of the 3 groups on day 7 (P= 0.903) with
the percentage of the patients with CSE being 46.4% in
Group 1, 45.3% in Group 2, and 51.3% in Group 3.
However, there was a statistically significant difference
between the 3 groups at day 21 (P= 0.006). On that day,
the percentage of the patients with CSE was the highest in
Group 3 (63.4%; n: 20) and the lowest in Group 1 (42.5%;
n: 14). The percentage of the patients with CSE in Group 2
(51.6%; n: 16) was higher than Group 1 and lower than
Group 3. Figure 1 shows the mean scores for CSE on the
first, seventh and twenty first days in all groups. Charts of
patients in Groups 1 and 2 with persistent CSE at the third
week (n: 30) were further examined for long term follow-
up results. Eight patients were lost from follow-up. The
remaining 22 patients were followed up for a minimum of
3 months (103.2± 8.4 days). Persistent CSE were treated
with low-potency topical corticosteroids in 12 patients
and topical 2% CsA in 10 patients. Four patients from the
group receiving topical corticosteroids and three patients
from the group receiving topical 2% CsA had persistent
CSE at the end of the follow-up period.
None of the patients in the three groups experienced
any local or systemic side effects necessitating the
cessation of therapy or a change in the treatment regimen,
except for two patients in Group 1 who had increased
intraocular pressure at the first week visit. Intraocular
pressure was normalised in these patients upon cessation
of topical corticosteroids.
Discussion
To the best of our knowledge, this is the first study
evaluating the performance of topical 2% Cyclosporin A
in the treatment of acute adenoviral conjunctivitis. We
also compared the clinical outcomes of patients receiving
topical corticosteroids, Cyclosporin A and only palliative
treatment. We observed that the symptoms were less
severe and had a shorter duration with topical
corticosteroids and CsA when compared with palliative
therapy and topical 2% CsA had an inhibitory effect on
the development of corneal subepithelial infiltrates when
used in the acute phase of infection, similar to
corticosteroids.
There is no currently available treatment that is
effective against adenoviral keratoconjunctivitis. Despite
the fact that this is a self-limiting disease, most affected
individuals seek and receive treatment as a result of the
severity of their symptoms.25 This may be the reason that
36% of eye care practitioners still prescribe topical
corticosteroids for epidemic keratokonjunctivitis.26 In a
randomised placebo-controlled trial including 111 viral
conjunctivitis patients, the group receiving topical
dexamethasone was significantly more likely to report
that they felt the drops helped than the group receiving
vehicle control drops.4 However, three other older reports
comparing topical steroids versus topical lubricants found
no difference in the amount of subepithelial infiltrates and
punctate epithelial keratitis, course of the disease and
symptoms.14,27,28
Cyclosporine is another agent explored for treating
symptoms caused by AAK. One study found accelerated
subjective improvement of local symptoms with 1%
cyclosporine eyedrops (4 times a day for 21 days), as
Figure 1 The mean clinical scores for corneal subepithelial
infiltrates on the first, seventh and twenty first days in Groups 1,
2 and 3. (Error bars indicating standard error of mean.)
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compared with 0.2% cidofovir or a combination of 0.2%
cidofovir+1% cyclosporine.20 In our study, we observed
that patients receiving topical corticosteroids experienced
the symptoms for a shorter period of time when
compared with the palliative treatment group. The mean
time until the resolution of the subjective symptoms was
significantly higher in patients receiving only artificial
tears and palliative treatment (13.3± 4.2 days), when
compared with patients receiving topical 2%
Cyclosporine A (11.2± 4.9 days) and topical 1%
prednisolone acetate (9.5± 4.9 days). Patients receiving
topical Cyclosporine A had a shorter duration of
symptoms when compared with patients receiving
palliative therapy as well.
We used the OSDI questionnaire in an attempt to
evaluate the symptomatic differences between groups
during the treatment period. The mean OSDI scores were
lower in patients receiving topical corticosteroids at every
visit and this difference was significant at days 7 and 21.
In patients receiving palliative treatment, the OSDI scores
were significantly higher than the patients receiving
topical corticosteroids at both visits. Patients receiving
topical CsA had similar OSDI scores to patients receiving
palliative treatment at each visit. The relatively high OSDI
scores in patients receiving topical CsA might be related
to the slight ocular discomfort caused by the cyclosporine
eye drops which was also reported by some patients in
this group.
The mean sum of clinical scores was highest in patients
receiving palliative treatment at all control visits and this
differrence was significant at day 21. There was no
significant difference between the mean sum of clinical
scores of patients receiving topical corticosteroids and
topical CsA at any visit. When we analysed each clinical
score seperately, there was no significant difference
among groups in terms of clinical scores for conjunctival
injection, conjunctival chemosis, and Schirmer’s test at
any visit. This is similar to the findings of the previous
literature comparing topical corticosterois with
lubricants.27
Corticosteroids are advised to be reserved until patients
present with a pseudomembrane or symptomatic
subepithelial infiltrates, however it is not known if they
have a preventive effect on the development of corneal
SEI when used in the acute phase of infection.29
Cyclosporine was specifically explored for treating
symptoms caused by subepithelial infiltrates.12,13,19,20 One
percent CsA administered 4 times a day for 21 days
during acute infection produced earlier subjective
improvement of local symptoms and a trend toward a
lower incidence of corneal opacities.20 In a second study,
the majority of patients with longstanding established
CSE were successfully treated with 2% CsA with
reduction or elimination of SEIs and successful weaning
off therapy.19 Similarly, Levinger et al13 reported
improvement in vision and satisfaction with topical 1%
CSA in 9 patients with subepithelial corneal infiltrates
secondary to adenoviral keratoconjunctivitis.
Romanowski et al found that treatment with both 2.0 and
0.5% CsA in the rabbit model significantly reduced the
formation of SEIs.12 In our study, at day 21, the
percentage of the patients with CSE was highest in the
palliative treatment group (63.4%) and lowest in topical
corticosteroid group (42.5%). The percentage of the
patients with CSE in the topical Cyclosporine group
(51.6% at day 21) was higher than patients receiving
topical corticosteroids and lower than patients receiving
topical lubricants. As a result it appears that topical
corticosteroids have an inhibitory effect on the
development of CSE when used in the acute phase of
infection and topical Cyclosporine A has a similar
inhibitory effect as well, although less potent.
There are two potential side effects from using topical
steroids to treat viral conjunctivitis: the promotion of viral
replication and the associated exacerbation of
unrecognised HSV infection. In our study, the diagnosis
was confirmed by an in-office lateral flow immunoassay,
RPS Adeno Detector (Rapid Pathogen Screening Inc.,
Sarasota, Florida, USA) in all patients thus, other causes
of viral conjunctivitis were ruled out. It is known that
topical steroids increase and prolong viral shedding in
rabbit models of adenoviral conjunctivitis, even when
given for as little as 3 days.30 Thus steroids could
exacerbate adenovirus infection in humans and cause
epidemic outbreaks. The same effect has been shown with
topical Cyclosporine A.12 Patients presenting with AAK
should be informed about the highly contagious nature of
the disease and the necessary precautions that should be
taken to minimise the spread of the disease in an attempt
to prevent epidemic outbreaks, especially in cases treated
with topical corticosteroids or CsA. The risk of using
corticosteroid or cyclosporine eye drops and possibly
prolonging and facilitating the spread of the infection
must be weighed against the clinical benefit of
symptomatic relief and the inhibitory effect on corneal
complications.
As a result, the symptoms were observed to be less
severe and had a shorter duration in patients receiving
topical corticosterois and topical CsA when compared
with patients receiving only palliative treatment.
Furthermore, it appears that topical 2% CsA has an
inhibitory effect on the development of CSE when used in
the early phase of infection, similar to topical
corticosteroids. This is a complication causing significant
potential of morbidity and visual loss. Topical 2%
Cyclosporin A had a similar effect to corticosteroids, with
the advantage of being a steroid-sparing agent. The most
important disadvantage of CsA therapy is the high cost
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when compared with topical corticosteroids and
lubricants. Further studies should focus on the use of
topical CsA for acute adenoviral keratoconjunctivitis and
prevention of its corneal complications, in different doses
and frequencies, as well as comparative studies with
corticosteroids including their effect on viral shedding.
Summary
What was known before
K The use of topical steroids is recommended only to reduce
scarring in severe cases of acute adenoviral
keratoconjunctivitis (AAK) with marked chemosis, lid
swelling, epithelial sloughing, or membranous
conjunctivitis. However, short term topical steroids are
still frequently used with an aim to decrease patient
discomfort.
K Topical Cyclosporin A, in different concentrations
(1 and 2%), is effective in the treatment of subepithelial
infiltrates during the chronic phase of AAK.
What this study adds
K The symptoms of acute adenoviral keratoconjunctivitis
AAK) may be less severe and have a shorter duration in
patients receiving topical corticosterois and topical CsA
when compared with patients receiving only topical
lubricants.
K Clinical signs associated with corneal subepthelial
infiltrates may be less severe in patients receiving topical
corticosteroids, as well as topical 2% Cyclosporin A.
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